- Home
- DSP vs NTHI Comparison
DSP vs NTHI Comparison
Compare DSP & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DSP | NTHI |
|---|---|---|
| Founded | 1999 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.3M | 195.5M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | DSP | NTHI |
|---|---|---|
| Price | $11.81 | $6.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $18.50 | N/A |
| AVG Volume (30 Days) | ★ 261.6K | 71.7K |
| Earning Date | 11-10-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.49 | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $324,131,000.00 | $59,990.00 |
| Revenue This Year | $17.79 | N/A |
| Revenue Next Year | $17.72 | N/A |
| P/E Ratio | $120.95 | ★ N/A |
| Revenue Growth | ★ 22.97 | N/A |
| 52 Week Low | $8.11 | $3.20 |
| 52 Week High | $26.33 | $25.00 |
Technical Indicators
Market Signals| Indicator | DSP | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 62.12 | 35.58 |
| Support Level | $11.10 | $8.63 |
| Resistance Level | $12.26 | $10.44 |
| Average True Range (ATR) | 0.50 | 0.93 |
| MACD | -0.02 | -0.21 |
| Stochastic Oscillator | 60.75 | 4.46 |
Price Performance
Historical ComparisonAbout DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).